Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE: Darunavir/Ritonavir in Treatment-Experienced HIV
NCT00381303Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV), sponsored by Johnson & Johnson. Primary endpoint: Percentage of Patients with Viral Load < 50 copies/mL at 48 weeks. Started Nov 2006; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00381303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381303.